Health technology and pharmaceutical marketing in 2026 sits across product classification, clinical evidence, medicine and device regulation, NHS adoption, professional promotion, patient information, data protection and rapidly changing AI rules. The commercial challenge is to explain innovation clearly without letting the marketing claim outrun the product’s intended purpose, evidence or permitted audience.
WLW FUTURE reviewed current MHRA AI and medical device activity, the 2024 ABPI Code currently published by PMCPA, MHRA medicines advertising guidance and current health data requirements. The strongest growth model starts by classifying what the product is, who the audience is and which claims the evidence can genuinely support.
250kpeople are sent to hospital by adverse drug reactions each year according to MHRA
£2bn+annual NHS cost attributed by MHRA to adverse drug reactions
7AI Airlock phase 2 case studies ran across the programme ending May 2026
2027full implementation target for the updated AI healthcare regulatory framework, subject to legislation
Research boundary
This benchmark covers commercial marketing and digital customer journeys across health technology, software and AI medical devices and pharmaceutical communications. Exact rules depend on product classification, authorisation, intended purpose, audience and territory.
This benchmark covers commercial marketing and digital customer journeys across health technology, software and AI medical devices and pharmaceutical communications. Exact rules depend on product classification, authorisation, intended purpose, audience and territory.
The headline findings for regulated health technology marketing in 2026
Product classification comes before positioning
MHRA says many software and AI products used in health and social care are regulated as medical devices. Marketing teams need to know whether the product is wellness software, a medical device, an IVD, an AI medical device or a medicine related service before claims are written.
AI regulation is actively changing
MHRA published National Commission evidence in June 2026 and launched new AI regulatory sandbox activity with NHS partners. The commercial environment is moving towards clearer real world evidence and post market oversight.
Intended purpose should control medical device claims
Draft 2026 device regulations include a requirement for manufacturers to align claims about devices with their statement of intended purpose.
Prescription medicine audiences must remain separated
Public advertising of POMs remains prohibited. The ABPI Code also requires digital promotional material for HCPs and public information to be clearly separated where both sit on the same website.
Digital promotion still needs mandatory information
ABPI Clause 12 says prescribing information in digital material accessed on a recipient’s own device can be included as text or through a clear prominent direct single click link.
Health data changes product growth tactics
Condition, diagnosis and treatment information can be special category data. Product analytics, CRM and advertising audiences need a separate data protection review.
AI healthcare regulation is moving from experimentation towards a new framework
The MHRA published findings from the National Commission into the Regulation of AI in Healthcare in June 2026 after research involving patients, health professionals, industry and system partners. The work is intended to inform recommendations for future AI healthcare regulation. MHRA AI Commission evidence
The London Region I MHRA Regulatory Sandbox opened for expressions of interest in July 2026, bringing AI enabled medical device manufacturers together with NHS organisations and regulatory experts to generate real world evidence of safety and effectiveness. MHRA London sandbox
The regulatory direction rewards evidence led adoption
Current MHRA programmes are focused on real world safety, effectiveness, clearer routes to adoption and stronger post market understanding.
7 case studiesAI Airlock phase 2 tested a range of AI as a medical device regulatory questions through seven case studies.MHRA
London sandboxThe 2026 programme links AI medical device manufacturers with NHS providers and regulators in a real world environment.MHRA
Claims alignmentDraft 2026 device regulations propose that medical device claims align with the manufacturer’s stated intended purpose.MHRA
Classify the product before the marketing team decides what it does
MHRA guidance says software and AI play an essential part in health and social care and many such products are regulated as medical devices or IVDs. Classification affects evidence, conformity, post market obligations and the language the company can safely use. MHRA software and AI guidance
| Product type | Marketing starting point | Main commercial risk | Priority |
|---|---|---|---|
| General wellness software | Can usually be marketed as a wellness service where claims stay within its actual purpose | Diagnostic or treatment claims can move the product towards medical device territory | Review |
| Software as a medical device | Claims should reflect intended purpose, classification and supporting evidence | Marketing a broader diagnosis, prediction or treatment benefit than the regulated purpose supports | High |
| AI medical device | Medical device requirements apply with additional challenges around model change, transparency and evidence | Using AI novelty claims as a substitute for validated clinical performance | High |
| Prescription medicine promotion to HCPs | Permitted within medicines law and ABPI Code requirements for relevant professional audiences | Public access, missing prescribing information, audience leakage or unbalanced claims | High |
| Disease awareness or public information | Can be provided when factual, balanced and non promotional | Content becoming an indirect route to encourage demand for a specific POM | Review |
Interactive regulated health marketing checker
Check the product, audience, claim and channel before launch
This screening tool exposes where positioning can move beyond intended purpose, permitted audience or evidence.
1. What is the product?
2. Who is the audience?
3. What is the strongest claim?
4. Which channel?
Lower risk starting point
Keep the product, audience and evidence aligned
A correctly classified product with audience appropriate claims has a more manageable marketing starting position.
Pharmaceutical promotion needs clear separation between HCPs and the public
The MHRA states that prescription only medicines cannot be advertised to the public but can be promoted to healthcare professionals and others who prescribe or supply them. The current ABPI Code published by PMCPA covers digital advertising, direct mail, representatives, meetings, public information and relationships with patient organisations. MHRA medicines advertising
ABPI Clause 16 says that where a pharmaceutical company website includes promotion for HCPs alongside public information, the intended audiences should be clearly separated so the public does not need to access professional promotional material unless they choose to. ABPI Clause 16
Evidence, intended purpose and claims need one approval route
In May 2026 the MHRA consulted on draft Medical Devices Amendment Regulations which included a proposal requiring manufacturers to align claims about medical devices with their statement of intended purpose. This is commercially significant because marketing teams often broaden the proposition as a product moves from clinical development into acquisition. MHRA device regulation consultation
Create an approved claims library
Connect intended purpose, clinical evidence, product documentation and approved commercial wording.
Separate evidence from aspiration
Roadmap language, pilot outcomes and validated performance should not be presented as interchangeable.
Give sales teams the same boundaries
Website, decks, events, outreach and account based marketing should use the same approved evidence.
Digital channels change distribution, not the underlying promotion rules
ABPI Clause 12 includes specific provisions for prescribing information in digital materials while Clause 26 covers public and patient information. Social media requires particular care because a public post can move beyond factual disease awareness into product promotion. ABPI Clause 26
Health technology growth frequently depends on sensitive data
Health technology products can process symptoms, diagnoses, test data, behavioural information and treatment decisions. Data used to deliver the product should not automatically become marketing data. ICO guidance treats health information as special category data and places additional requirements on direct marketing and profiling. ICO direct marketing guidance
The strongest health technology buyer journey moves from evidence to implementation
1. ProblemThe buyer recognises a clinical, operational, financial or patient access problem worth solving.
2. EvidenceThe product explains intended purpose, validated performance, safety, interoperability and relevant regulatory status.
3. FitClinical, procurement, information governance and technical stakeholders can assess whether the product fits the service.
4. PilotReal world evidence, implementation support and clear success measures reduce adoption risk.
5. ScaleCommercial expansion follows evidence, governance, integration and measurable service value.
Benchmark your health technology and pharmaceutical digital setup
Current benchmark score
0/10
Start with product classification and evidence
Connect regulatory status, intended purpose, audience, approved claims, digital distribution, health data and commercial measurement.
Where regulated health technology growth remains
Own category education
Build authoritative content around the problem, intended purpose, evidence and implementation questions.
Map stakeholder journeys
Clinical, procurement, IT, finance and patient audiences need different information and conversion routes.
Turn regulation into credibility
Clear classification, conformity and evidence can strengthen trust with enterprise buyers.
Use pilots as commercial proof
Translate real world deployment into measurable case evidence without overstating what the study proves.
Connect pipeline to adoption
Measure qualified opportunities, pilots, procurement stages and implementation value rather than lead volume alone.
Build AI citation readiness
Use clear product definitions, evidence summaries and structured technical information so AI systems can understand the offer accurately.
WLW FUTURE regulated health technology digital opportunity review
See where your product story is exposed and where it can grow
WLW FUTURE can review product positioning, regulated claims, search and AI visibility, buyer journeys, paid media, outreach, health data use and commercial conversion together.
Request a health technology digital opportunity reviewFrequently asked questions
Is health software always a medical device?
No. Classification depends on intended purpose and functionality. MHRA says many health software and AI products are medical devices, but general wellness software can fall outside medical device regulation where it does not meet the relevant criteria.
Can pharmaceutical companies promote prescription medicines to the public?
No. Prescription only medicines cannot be advertised to the public in the UK. Promotion can be directed to healthcare professionals and other relevant decision makers within applicable requirements.
Can a company put HCP and patient information on the same website?
Yes, but ABPI guidance says promotional POM material for professional audiences and public information should be clearly separated and the intended audience identified.
Why does intended purpose matter to device marketing?
It defines what the medical device is intended to do. Draft 2026 device regulations include a proposal that manufacturers align claims about devices with the stated intended purpose.
Sources and methodology
- MHRA software and AI as a medical device guidance.
- National Commission into the Regulation of AI in Healthcare evidence. June 2026.
- MHRA AI Airlock phase 2 programme report. June 2026.
- London Region I MHRA Regulatory Sandbox. July 2026.
- Draft Medical Devices Amendment Regulations 2026 consultation.
- MHRA: Advertise your medicines.
- ABPI Code of Practice for the Pharmaceutical Industry 2024.
- ABPI Clause 16: Material and Distribution.
- ABPI Clause 26: Relations with the public.
- ICO direct marketing guidance.
Commercial methodology: The risk checker and benchmark are WLW FUTURE planning tools. Exact requirements depend on product classification, authorisation, audience, territory and use case.
